文献速递药物不良反应与药物警戒

儿科发育安全性评估与新型替代方法:美国FDA/Triangle CERSI研讨会报告

Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report.
PubMed 文献 · Clin Pharmacol Ther · 2026-10-02

美国FDA临床药理学办公室与Triangle CERSI召开研讨会,探讨儿科发育安全性评估的新型替代方法(NAMs)。会议围绕次要药理学筛选工具、非临床工具和计算数据驱动工具三个主题,在S11和E11A指南框架下讨论,结论认为NAMs在推进儿科药物发育安全性评估方面具有显著前景。

要点

  • 儿科发育安全性评估面临器官系统和药物处置途径动态变化的独特挑战。
  • 主要来自成人的药物警戒数据并不总能预测儿童反应。
  • NAMs在推进儿科药物发育安全性评估方面具有显著前景。

核心结论

  • 研讨会结论认为NAMs在推进儿科药物发育安全性评估方面具有显著前景。

研究设计与样本

  • 美国FDA临床药理学办公室与Triangle CERSI联合召开研讨会,参会者来自监管机构、学术界和工业界。

主要发现

  • 儿童发育过程中器官系统和药物处置途径动态变化,药物相关效应可能延迟或表现与成人不同。
  • 主要来自成人的药物警戒数据并不总能预测儿童反应。
  • 历史上幼年动物研究专用于非临床儿科药物安全性评估,但减少动物试验是公共卫生机构的目标。

关键数值与推荐

  • 讨论在S11儿科药物非临床安全性测试和E11A儿科外推指南框架下进行,促进结构化、基于问题的儿科外推。
  • 讨论聚焦三个主题:次要药理学筛选工具、非临床工具、计算与数据驱动工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric developmental safety assessment presents distinct challenges in drug development. Children undergo dynamic changes in organ systems and drug disposition pathways during development, and drug-related effects may be delayed or manifested differently than in adults. Pharmacovigilance data, primarily from adults, is not always predictive of the response in children. Historically, juvenile animal studies have been used for nonclinical pediatric drug safety assessments exclusively, but the reduction in animal testing is a goal of public health agencies. To address this concern, the Office of Clinical Pharmacology at the U.S. FDA and the Triangle CERSI (Center of Excellence in Regulatory Science and Innovation) convened a workshop entitled: "Pediatric Developmental Safety Assessment and New Approach Methodologies (NAMs)," attended by experts from regulatory agencies, academia, and industry. Discussions focused on three overarching topics: (i) Secondary Pharmacology Screening Tools for Assessing Pediatric Developmental Safety; (ii) Non-clinical Tools for Pediatric Developmental Safety Assessment; and (iii) Computational and Data-Driven Tools for Pediatric Developmental Safety. These topics were examined within the framework of the S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals and E11A Pediatric Extrapolation guidances, which promote structured, question-based pediatric extrapolation in drug development and authorization. The workshop concluded that NAMs hold considerable promise to advance the assessment of pediatric drug developmental safety.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Burckart GJ, Abulwerdi G, Daniels CL, et al. Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report. Clin Pharmacol Ther. 2026. PMID: 42823916. doi:10.1002/cpt.70493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。